Scientist Jailed for Gene Hacking Babies Says Ethics Are Holding Back Progress
By Luis Prada,
Vice
| 03. 14. 2025
public domain photo by Voice of America via Wikimedia Commons
Back in 2019, Chinese biophysicist He Jiankui proudly announced to the world that he had created two genetically edited human babies, fully expecting a round of applause and three cheers of “Hip Hip Hooray.” Instead, everyone booed him and he got thrown in prison for three years.
He’s since been released from prison, though it doesn’t seem like he’s learned any lessons from his stint in the clink. This was demonstrated by a post on Twitter/X wherein he accompanied a soulless picture of himself in a tweet in which he says that “ethics is holding back scientific innovation and progress.”
Now, you might recognize that is the kind of thing a villain says before he splices into your DNA, unforeseen consequences be damned. Jiankui used CRISPR gene-editing technology to edit the DNA of a set of twins codenamed “Nana” and “Lulu” to make them immune to HIV. Sounds like a noble goal, until you find out that fiddling with those genes to make the girls immune to HIV could...
Related Articles
By Mike McIntire, The New York Times | 01.24.2026
Genetic researchers were seeking children for an ambitious, federally funded project to track brain development — a study that they told families could yield invaluable discoveries about DNA’s impact on behavior and disease.
They also promised that the children’s sensitive...
By Arthur Lazarus, MedPage Today | 01.23.2026
A growing body of contemporary research and reporting exposes how old ideas can find new life when repurposed within modern systems of medicine, technology, and public policy. Over the last decade, several trends have converged:
- The rise of polygenic scoring...
By Danny Finley, Bill of Health | 01.08.2026
The United States Food and Drug Administration (FDA) has a unique funding structure among federal scientific and health agencies. The industries it regulates fund nearly half of its budget. The agency charges companies a user fee for each application
...
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...